[{"id":"91fb4f60-829a-4224-bfce-3668ff6fda2a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04771520","created_at":"2021-02-25T15:52:21.802Z","updated_at":"2025-02-25T14:15:51.905Z","phase":"Phase 2","brief_title":"Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors","source_id_and_acronym":"NCT04771520","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PDGFRA","pipe":" | ","alterations":" PDGFRA mutation","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 01/20/2021","start_date":" 01/20/2021","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-17"},{"id":"d1bc1259-71d0-45e4-a4ce-99f4232d61c4","acronym":"AZURE","url":"https://clinicaltrials.gov/study/NCT05609942","created_at":"2023-04-03T15:02:58.943Z","updated_at":"2025-02-25T14:41:39.851Z","phase":"Phase 1","brief_title":"Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies","source_id_and_acronym":"NCT05609942 - AZURE","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" PDGFRA","pipe":" | ","alterations":" KIT mutation • PDGFRA D842V • PDGFRA mutation","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • PDGFRA D842V • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • elenestinib (BLU-263)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 09/25/2023","start_date":" 09/25/2023","primary_txt":" Primary completion: 01/14/2025","primary_completion_date":" 01/14/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-14"},{"id":"67176e4e-5f06-435a-a426-189730ad7d5a","acronym":"LITESPARK-015","url":"https://clinicaltrials.gov/study/NCT04924075","created_at":"2021-07-05T17:36:40.354Z","updated_at":"2025-02-25T15:26:55.556Z","phase":"Phase 2","brief_title":"Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)","source_id_and_acronym":"NCT04924075 - LITESPARK-015","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" KIT • PDGFRA • VHL • EPAS1","pipe":" | ","alterations":" PDGFRA mutation","tags":["KIT • PDGFRA • VHL • EPAS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Welireg (belzutifan)"],"overall_status":"Recruiting","enrollment":" Enrollment 322","initiation":"Initiation: 08/12/2021","start_date":" 08/12/2021","primary_txt":" Primary completion: 06/04/2029","primary_completion_date":" 06/04/2029","study_txt":" Completion: 06/04/2029","study_completion_date":" 06/04/2029","last_update_posted":"2025-02-11"},{"id":"7ae66fef-a243-4d8f-b364-a73eb3507cdb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04633122","created_at":"2021-01-19T20:36:54.322Z","updated_at":"2025-02-25T15:34:48.949Z","phase":"Phase 2","brief_title":"A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib","source_id_and_acronym":"NCT04633122","lead_sponsor":"Zai Lab (Shanghai) Co., Ltd.","biomarkers":" KIT • PDGFRA","pipe":" | ","alterations":" KIT mutation • PDGFRA mutation","tags":["KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • sunitinib • Qinlock (ripretinib)"],"overall_status":"Completed","enrollment":" Enrollment 108","initiation":"Initiation: 11/25/2020","start_date":" 11/25/2020","primary_txt":" Primary completion: 07/20/2022","primary_completion_date":" 07/20/2022","study_txt":" Completion: 07/20/2022","study_completion_date":" 07/20/2022","last_update_posted":"2025-02-10"},{"id":"b25768d2-e63d-4ef1-89e9-0d4fc5455a84","acronym":"StrateGIST 1","url":"https://clinicaltrials.gov/study/NCT05489237","created_at":"2022-08-05T13:57:06.723Z","updated_at":"2025-02-25T13:13:05.882Z","phase":"Phase 1","brief_title":"First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors","source_id_and_acronym":"NCT05489237 - StrateGIST 1","lead_sponsor":"IDRx, Inc.","biomarkers":" PDGFRA","pipe":" | ","alterations":" KIT mutation • PDGFRA mutation • PDGFRA exon 18 mutation","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • PDGFRA mutation • PDGFRA exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • velzatinib (GSK6042981)"],"overall_status":"Recruiting","enrollment":" Enrollment 269","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 04/24/2026","primary_completion_date":" 04/24/2026","study_txt":" Completion: 09/13/2026","study_completion_date":" 09/13/2026","last_update_posted":"2025-01-17"},{"id":"ddcdaa98-710f-4836-a6b4-89e5e80022ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT05957367","created_at":"2023-07-24T15:08:40.775Z","updated_at":"2024-07-02T16:34:59.920Z","phase":"Phase 1/2","brief_title":"A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies","source_id_and_acronym":"NCT05957367","lead_sponsor":"Deciphera Pharmaceuticals LLC","biomarkers":" BRAF • KIT • PDGFRA","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • KIT mutation • KIT exon 11 mutation • PDGFRA mutation","tags":["BRAF • KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • KIT mutation • KIT exon 11 mutation • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Braftovi (encorafenib) • Qinlock (ripretinib) • inlexisertib (DCC-3116)"],"overall_status":"Recruiting","enrollment":" Enrollment 94","initiation":"Initiation: 09/28/2023","start_date":" 09/28/2023","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-05-31"},{"id":"f0120f59-10df-43f7-b5bb-987a4f3afad2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05493215","created_at":"2022-08-09T17:04:45.434Z","updated_at":"2024-07-02T16:35:12.164Z","phase":"Phase 2","brief_title":"Imatinib TDM in GIST","source_id_and_acronym":"NCT05493215","lead_sponsor":"Reema A. Patel","biomarkers":" KIT • PDGFRA","pipe":" | ","alterations":" KIT mutation • PDGFRA D842V • PDGFRA mutation","tags":["KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • PDGFRA D842V • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 03/26/2024","start_date":" 03/26/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-01"},{"id":"bf439f30-e0dc-43f8-a4c4-f4b1f0fa3a26","acronym":"","url":"https://clinicaltrials.gov/study/NCT02571036","created_at":"2021-01-17T17:36:28.986Z","updated_at":"2024-07-02T16:35:26.428Z","phase":"Phase 1","brief_title":"A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies","source_id_and_acronym":"NCT02571036","lead_sponsor":"Deciphera Pharmaceuticals LLC","biomarkers":" KIT • PDGFRA","pipe":" | ","alterations":" KIT mutation • PDGFRA mutation • KIT amplification","tags":["KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • PDGFRA mutation • KIT amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Qinlock (ripretinib)"],"overall_status":"Completed","enrollment":" Enrollment 282","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 04/29/2022","primary_completion_date":" 04/29/2022","study_txt":" Completion: 04/29/2022","study_completion_date":" 04/29/2022","last_update_posted":"2023-12-13"},{"id":"db898d9d-a02c-48cb-a0b4-34daa92cee0f","acronym":"GIST","url":"https://clinicaltrials.gov/study/NCT04821895","created_at":"2021-03-30T11:52:14.450Z","updated_at":"2024-07-02T16:35:29.735Z","phase":"","brief_title":"Oncogenetic Panel and Integrated Clinical Data Registry Study for Wild Type Gastrointestinal Stromal Tumor Patients","source_id_and_acronym":"NCT04821895 - GIST","lead_sponsor":"National Health Research Institutes, Taiwan","biomarkers":" KIT • PDGFRA","pipe":" | ","alterations":" PDGFRA mutation • KIT wild-type • PDGFR wild-type","tags":["KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA mutation • KIT wild-type • PDGFR wild-type"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 08/28/2021","start_date":" 08/28/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2023-11-09"},{"id":"ff971a31-4620-40ce-aa35-33a25eb28431","acronym":"","url":"https://clinicaltrials.gov/study/NCT02413736","created_at":"2021-01-18T11:31:48.616Z","updated_at":"2024-07-02T16:35:29.677Z","phase":"Phase 3","brief_title":"Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST","source_id_and_acronym":"NCT02413736","lead_sponsor":"Heikki Joensuu","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" KIT mutation • PDGFRA mutation","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 255","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2033","study_completion_date":" 05/01/2033","last_update_posted":"2023-11-09"},{"id":"9311c6a1-8eb7-4bef-bf44-cda43d3d097a","acronym":"ALT GIST","url":"https://clinicaltrials.gov/study/NCT02365441","created_at":"2021-01-18T11:15:45.915Z","updated_at":"2024-07-02T16:35:43.660Z","phase":"Phase 2","brief_title":"A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)","source_id_and_acronym":"NCT02365441 - ALT GIST","lead_sponsor":"Australasian Gastro-Intestinal Trials Group","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" PDGFRA mutation","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • Stivarga (regorafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 06/30/2015","start_date":" 06/30/2015","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-07-07"},{"id":"c402eaa9-bf76-4b0d-b1a4-4b7d8a779eb5","acronym":"BLU-285-3101","url":"https://clinicaltrials.gov/study/NCT04773782","created_at":"2021-02-26T12:55:17.604Z","updated_at":"2024-07-02T16:35:45.622Z","phase":"Phase 1/2","brief_title":"A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling","source_id_and_acronym":"NCT04773782 - BLU-285-3101","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" KIT • PDGFRA","pipe":" | ","alterations":" PDGFRA mutation","tags":["KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 02/24/2022","start_date":" 02/24/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2023-06-15"},{"id":"fa33bd39-1991-4c6f-a15f-60d817bf8b15","acronym":"SeliGIST","url":"https://clinicaltrials.gov/study/NCT04138381","created_at":"2021-01-18T20:18:27.936Z","updated_at":"2024-07-02T16:35:52.291Z","phase":"Phase 1/2","brief_title":"Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST)","source_id_and_acronym":"NCT04138381 - SeliGIST","lead_sponsor":"Grupo Espanol de Investigacion en Sarcomas","biomarkers":" KIT • PDGFRA","pipe":" | ","alterations":" PDGFRA mutation","tags":["KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • Xpovio (selinexor)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/16/2019","start_date":" 08/16/2019","primary_txt":" Primary completion: 04/16/2023","primary_completion_date":" 04/16/2023","study_txt":" Completion: 04/16/2023","study_completion_date":" 04/16/2023","last_update_posted":"2023-03-27"},{"id":"beae3831-e867-4796-98b5-a4cab6099ed8","acronym":"NAVIGATOR","url":"https://clinicaltrials.gov/study/NCT02508532","created_at":"2021-01-17T17:33:18.563Z","updated_at":"2024-07-02T16:36:08.544Z","phase":"Phase 1","brief_title":"(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors","source_id_and_acronym":"NCT02508532 - NAVIGATOR","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" KIT • PDGFRA","pipe":" | ","alterations":" PDGFRA D842V • PDGFRA mutation","tags":["KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA D842V • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib)"],"overall_status":"Completed","enrollment":" Enrollment 250","initiation":"Initiation: 08/01/2015","start_date":" 08/01/2015","primary_txt":" Primary completion: 03/06/2020","primary_completion_date":" 03/06/2020","study_txt":" Completion: 06/03/2021","study_completion_date":" 06/03/2021","last_update_posted":"2022-06-21"},{"id":"057c88c5-edbb-41d4-a61e-3b9b94a6ba2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02924714","created_at":"2021-01-18T14:21:47.438Z","updated_at":"2025-02-25T16:31:00.901Z","phase":"","brief_title":"SSG XXV: The Stop-GIST Trial; Discontinuation of Imatinib in Patients With Oligo-metastatic GIST","source_id_and_acronym":"NCT02924714","lead_sponsor":"Oslo University Hospital","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" PDGFRA mutation","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Suspended","enrollment":" Enrollment 31","initiation":"Initiation: 01/01/2017","start_date":" 01/01/2017","primary_txt":" Primary completion: 11/01/2022","primary_completion_date":" 11/01/2022","study_txt":" Completion: 11/01/2022","study_completion_date":" 11/01/2022","last_update_posted":"2022-02-18"},{"id":"65aa546b-6373-4d3e-bd0b-ba34a643210e","acronym":"ZJGIST-01","url":"https://clinicaltrials.gov/study/NCT04933669","created_at":"2021-06-22T15:52:32.553Z","updated_at":"2024-07-02T16:36:23.163Z","phase":"Phase 2","brief_title":"Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors","source_id_and_acronym":"NCT04933669 - ZJGIST-01","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" KIT mutation • KIT exon 11 mutation • KIT exon 9 mutation • KIT positive • PDGFRA mutation • KIT exon 13 mutation • KIT exon 17 mutation","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT exon 11 mutation • KIT exon 9 mutation • KIT positive • PDGFRA mutation • KIT exon 13 mutation • KIT exon 17 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Recruiting","enrollment":" Enrollment 122","initiation":"Initiation: 09/07/2021","start_date":" 09/07/2021","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2021-10-12"},{"id":"ec0044ab-0bc9-4c5a-8f2a-82680d79f10c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02847429","created_at":"2021-01-18T13:58:42.892Z","updated_at":"2024-07-02T16:36:35.764Z","phase":"Phase 3","brief_title":"Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST","source_id_and_acronym":"NCT02847429","lead_sponsor":"Arog Pharmaceuticals, Inc.","biomarkers":" PDGFRA","pipe":" | ","alterations":" PDGFRA D842V • PDGFRA mutation","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA D842V • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e crenolanib (ARO-002)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 08/01/2021","primary_completion_date":" 08/01/2021","study_txt":" Completion: 08/01/2021","study_completion_date":" 08/01/2021","last_update_posted":"2021-01-22"},{"id":"bbe275ad-6be5-4313-a449-5847e6c48405","acronym":"CYCLIGIST","url":"https://clinicaltrials.gov/study/NCT01907607","created_at":"2021-01-18T08:35:33.854Z","updated_at":"2024-07-02T16:36:35.901Z","phase":"Phase 2","brief_title":"Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib","source_id_and_acronym":"NCT01907607 - CYCLIGIST","lead_sponsor":"Institut Bergonié","biomarkers":" KIT • CDKN2A • PDGFRA • ANO1","pipe":" | ","alterations":" CDKN2A deletion • PDGFRA mutation","tags":["KIT • CDKN2A • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A deletion • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • imatinib • sunitinib"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 02/01/2014","start_date":" 02/01/2014","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 02/01/2019","study_completion_date":" 02/01/2019","last_update_posted":"2021-01-20"},{"id":"28db9516-1c03-4c8b-98d1-37ee5af86d30","acronym":"","url":"https://clinicaltrials.gov/study/NCT03862885","created_at":"2021-01-18T19:03:16.863Z","updated_at":"2024-07-02T16:36:42.722Z","phase":"","brief_title":"Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST","source_id_and_acronym":"NCT03862885","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" PDGFRA","pipe":" | ","alterations":" PDGFRA D842V • PDGFRA mutation • PDGFRA exon 18 mutation","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA D842V • PDGFRA mutation • PDGFRA exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib)"],"overall_status":"Approved for marketing","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2020-07-27"},{"id":"740d476e-ff93-40d1-91bf-55a32e44d2cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT02015065","created_at":"2021-01-18T09:12:59.306Z","updated_at":"2024-07-02T16:36:47.258Z","phase":"Phase 2","brief_title":"Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors","source_id_and_acronym":"NCT02015065","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PDGFRA","pipe":" | ","alterations":" PDGFRA mutation","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Caprelsa (vandetanib)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 12/14/2013","start_date":" 12/14/2013","primary_txt":" Primary completion: 05/04/2016","primary_completion_date":" 05/04/2016","study_txt":" Completion: 12/10/2019","study_completion_date":" 12/10/2019","last_update_posted":"2020-03-30"},{"id":"9d81cf1f-46fe-4cab-9f02-d655ce986021","acronym":"AXAGIST","url":"https://clinicaltrials.gov/study/NCT04258956","created_at":"2021-01-18T20:41:54.526Z","updated_at":"2024-07-02T16:36:50.377Z","phase":"Phase 2","brief_title":"A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy","source_id_and_acronym":"NCT04258956 - AXAGIST","lead_sponsor":"Maria Sklodowska-Curie Institute - Oncology Center","biomarkers":" KIT • PDGFRA","pipe":" | ","alterations":" KIT mutation • PDGFRA mutation","tags":["KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • axitinib"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 04/30/2019","start_date":" 04/30/2019","primary_txt":" Primary completion: 04/30/2021","primary_completion_date":" 04/30/2021","study_txt":" Completion: 04/30/2023","study_completion_date":" 04/30/2023","last_update_posted":"2020-02-06"},{"id":"57c81b9c-1589-48e6-af8a-b8850f1fe404","acronym":"","url":"https://clinicaltrials.gov/study/NCT03923400","created_at":"2021-01-18T19:18:05.505Z","updated_at":"2024-07-02T16:37:00.373Z","phase":"","brief_title":"Jejunoileal vs Gastric GIST in the Era of Imatinib.","source_id_and_acronym":"NCT03923400","lead_sponsor":"Hospital Universitario Virgen de la Arrixaca","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" KIT mutation • KIT positive • PDGFRA mutation • KIT expression","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT positive • PDGFRA mutation • KIT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Completed","enrollment":" Enrollment 77","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 01/31/2017","primary_completion_date":" 01/31/2017","study_txt":" Completion: 01/31/2017","study_completion_date":" 01/31/2017","last_update_posted":"2019-04-22"},{"id":"57ca050d-286a-4326-a668-4807cb879ac1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03109301","created_at":"2021-01-18T15:19:11.134Z","updated_at":"2024-07-02T16:37:00.871Z","phase":"Phase 2","brief_title":"Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)","source_id_and_acronym":"NCT03109301","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KIT • PDGFRA • NF1","pipe":" | ","alterations":" KIT mutation • NF1 mutation • PDGFRA mutation","tags":["KIT • PDGFRA • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • NF1 mutation • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/07/2017","start_date":" 04/07/2017","primary_txt":" Primary completion: 03/27/2019","primary_completion_date":" 03/27/2019","study_txt":" Completion: 03/27/2019","study_completion_date":" 03/27/2019","last_update_posted":"2019-04-05"},{"id":"4ed8fa9f-6144-4f0c-b60f-f530e4d76c83","acronym":"","url":"https://clinicaltrials.gov/study/NCT01243346","created_at":"2021-01-17T17:54:43.344Z","updated_at":"2024-07-02T16:37:09.392Z","phase":"Phase 2","brief_title":"Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene","source_id_and_acronym":"NCT01243346","lead_sponsor":"Arog Pharmaceuticals, Inc.","biomarkers":" PDGFRA","pipe":" | ","alterations":" PDGFRA D842V • PDGFRA mutation","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA D842V • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e crenolanib (ARO-002)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 07/01/2014","primary_completion_date":" 07/01/2014","study_txt":" Completion: 07/01/2014","study_completion_date":" 07/01/2014","last_update_posted":"2018-06-28"}]